Journals / Namık Kemal Tıp Dergisi / 2019 / Cilt: 7 - Sayı: 3

The Predictive Value of ALBI and P-ALBI Scores in The Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B and Chronic Hepatitis B+D Induced Cirrhosis

KRONİK HEPATİT B VE B+D KAYNAKLI SİROZDA, HEPATOSELÜLER KARSİNOM GELİŞİMİNİN ÖNGÖRÜLMESİNDE ALBI VE PALBI SKORLAMALARININ PREDİKTİF DEĞERİ

Pages
172–179
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion:Although ALBI and PALBI have been developed to predict the survival and prognosis of HCC, we concluded that ALBI and PALBI may also be useful predictors of HCC development in cirrhosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim:Hepatocellular carcinoma (HCC) is the second most common cause of cancer related deaths worldwide.
📊
Key Findings & Data:Materials and Methods:331 patients with liver cirrhosis due to chronic hepatitis B and chronic hepatitis B + D who were admitted to Demiroğlu Bilim University between 2004-2019 were included in the study.
💡
Conclusion & Impact:Conclusion:Although ALBI and PALBI have been developed to predict the survival and prognosis of HCC, we concluded that ALBI and PALBI may also be useful predictors of HCC development in cirrhosis.
🔬Design:Research Article
📍Scope:2004-2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim:Hepatocellular carcinoma (HCC) is the second most common cause of cancer related deaths worldwide. Therefore, early diagnosis is too important for HCC. The aim of this study was to evaluate the predictive value of albumin-bilirubin index (ALBI) and platelet-albumin-bilirubin index (PALBI) on the development of HCC in patients withcirrhosis. Materials and Methods:331 patients with liver cirrhosis due to chronic hepatitis B and chronic hepatitis B + D who were admitted to Demiroğlu Bilim University between 2004-2019 were included in the study. The patients were divided into two main groups, with and without HCC. Demographic data, body mass index (BMI), Child and MELD scores and laboratory findings of the patients were recorded and analyzed separately for the groups. Mean ALBI and PALBI values were calculated for both groups. The relationships between ALBI, PALBI and HCC wereevaluated. Results:The mean age of the patients was 51.3 ± 9.18 and, the mean BMI was 30.04 ± 11.65. The HCC group consisted of 115 patients and the non-HCC cirrhosis group consisted of 216 patients. Mean ALBI and PALBI score values were significantly lower in HCC group than in non-HCC cirrhosis group (p<0,001). Area under curve values (AUC) were calculated 0.775 for the ALBI and 0.733 for thePALBI. Conclusion:Although ALBI and PALBI have been developed to predict the survival and prognosis of HCC, we concluded that ALBI and PALBI may also be useful predictors of HCC development in cirrhosis.

Özet

Amaç:Hepatosellüler karsinom (HCC), dünya çapında kanser kaynaklı ölümlerin ikinci en sık nedenidir. Bu nedenle, HCC’de erken tanı çok önemlidir. Bu çalışmanın amacı, sirozlu hastalarda HCC gelişiminde albumin-bilirubin indeksi (ALBI) ve Platelet- albumin-bilirubin indeksinin (PALBI) prediktivitelerinin değerlendirilmesidir. Materyal ve Metot:Çalışmaya 2004-2019 yılları arasında Demiroğlu Bilim Üniversitesi'ne başvuran kronik hepatit B ve kronik hepatit B + D ‘ ye bağlı karaciğer sirozlu 331 hasta dahil edildi. Hastalar HCC olan ve HCC olmayan olmak üzere iki ana gruba ayrıldı. Hastaların demografik verileri, vücut kitle indeksleri (VKİ), Child ve MELD skorları ve laboratuvar bulguları gruplar için ayrı ayrı kaydedildi ve analiz edildi. Her iki grup için ortalama ALBI ve PALBI değerleri hesaplandı. ALBI, PALBI ve HCC arasındaki ilişkilerdeğerlendirildi. Bulgular:Hastaların yaş ortalaması 51.3 ± 9.18, ortalama BKİ 30.04 ± 11.65 idi. HCC grubu 115 hastadan ve HCC olmayan siroz grubu 216 hastadan oluşmaktaydı. Ortalama ALBI ve PALBI skor değerleri, HCC grubunda HCC olmayan siroz grubuna göre anlamlı derecede düşüktü (p <0,001). Eğri altındaki değerler ALBI için 0.775 ve PALBI için 0.733idi. Sonuç:Her ne kadar ALBI ve PALBI, HCC' de sağkalım ve prognozu tahmin etmek için geliştirilse de, çalışmamızda ALBI ve PALBI' nin sirozda HCC gelişiminin tahmininde de yararlı belirleyiciler olabileceği sonucuna varıldı.

🔖

Cite This Article

ŞAHİN, T., ORAL, A. (2019). The Predictive Value of ALBI and P-ALBI Scores in The Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B and Chronic Hepatitis B+D Induced Cirrhosis. Namık Kemal Tıp Dergisi, Cilt: 7 - Sayı: 3, 172–179. https://ajindex.com/articles/289054

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87–108
  2. Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol 2015; 13:2140–51
  3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365(12):1118-27, 4. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17(6):1471–4
  4. Forner A, Reig ME, De Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010; 30(1): 61–74
  5. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 56(4):918–28
  6. Gallo C. Capuano G, Daniele B, Gaeta GB, Perrone F, Pignata S. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998; 28(3):751–5
  7. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000; 32(6):1224–9
  8. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiologicalcharacteristics and disease burden. J Viral Hepat. 2009; 16(7):453–63
  9. Perz JF, Armstrong GL, Farrington LA, Huntin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol.2006;45(4):529-38
  10. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010; 7(8): 448-58 12. Zhu WW, Guo JJ, Guo L, Jia HL, Zhu M, Zhang JB, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res. 2013;19:3944-54
  11. Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol.2014;28(5):843-53
  12. Wang T, Liu M, Zheng SJ, Bian DD, Zhang JY, Yao J, et al. Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis of α-fetoprotein- negative hepatocellular carcinoma. World J Gastroenterol. 2017; 23(1